FrancophonIA/ELRC3.0 huggingface dataset:
English: 4b recommendation: Regardless of the dog's body weight, using the applicator tip, part the hair at the base of the tail and begin applying the veterinary medicinal product directly onto the skin in a continuous line from the base of the tail along the centre of the back all the way up to the shoulder blades, as shown in the diagram, squeezing the applicator until it is empty.
Danish: 4b-anbefalinger: uanset hundens legemsvægt laves med applikatorspidsen en skilning ved halebasis og veterinærlægemidlet påføres direkte på huden i en ubrudt linje fra halebasis til midt på ryggen og hele vejen op til skulderbladene som vist på illustrationen.
English: Special precautions for use in animals
Danish: Særlige forholdsregler til brug hos dyr
English: It also prevents multiplication of fleas for two months after application by inhibiting egg hatching (ovicidal activity) and by inhibiting the emergence of adults from eggs laid by adult fleas (larvicidal activity).
Danish: Efter applikation forhindres i to måneder ligeledes opformeringen af lopper ved hæmning af ægklækningen (ovocidal aktivitet) og ved at hæmme fremkomsten af voksne individer fra de æg, der allerede måtte være lagt af voksne lopper (larvicidal aktivitet)
English: The veterinary medicinal product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks).
Danish: Veterinærlægemidlet har vedvarende acaricidal og repellerende (afvisende) effekt mod flåtinfestationer (Rhipicephalus sanguineus og Ixodes ricinus i en måned, og Dermacentor reticulatus i op til tre uger).
English: Gastrointestinal (stomach or gut) adverse reactions, such as vomiting or diarrhoea, have also been reported very rarely.
Danish: Gastrointestinale (mave og tarm) bivirkninger som opkast og diarré er ligeledes meget sjældent rapporteret.
English: for dogs 1.5-4 kg
Danish: til hunde 1.5-4 kg
English: This veterinary medicine kills and repels ticks (Rhipicephalus sanguineus and Ixodes ricinus ticks are controlled for one month; Dermacentor reticulatus ticks are controlled for up to three weeks).
Danish: Dette veterinærlægemiddel dræber og afskrækker flåter (Rhipicephalus sanguineus og Ixodes ricinus i en måned, og Dermacentor reticulatus i op til tre uger).
English: Blue for dogs > 25-40 kg
Danish: Blå til hunde > 25-40 kg
English: N-methylpyrrolidone, an excipient in the veterinary medicine, has been shown to cause foetal malformations leading to birth defects in laboratory animals.
Danish: Et af veterinærlægemidlets hjælpestoffer N-methylpyrrolidon er påvist at kunne medføre misdannelser hos laboratoriedyr.
English: Transient skin redness, itching or other signs of discomfort at the application site have been reported rarely and usually disappear without any treatment and within 24 hours after using the veterinary medicine.
Danish: Forbigående rødme, kløe og andre symptomer på ubehag på applikationsstedet er rapporteret i sjældne tilfælde og forsvinder sædvanligvis spontant inden for et døgn efter administration af veterinærlægemidlet.
English: The safety of the veterinary medicinal product in bitches has not been established during pregnancy and lactation.
Danish: Veterinærlægemidlets sikkerhed under tævehundens drægtighed og laktation er ikke fastlagt.
English: This prevents infestation within the environment of the treated animal.
Danish: Dette forhindrer, at hunden infesteres fra omgivelserne.
English: It is effective against the following fleas found on dogs (Ctenocephalides canis and Ctenocephalides felis).
Danish: Det er effektivt mod loppearterne Ctenocephalides felis og Ctenocephalides canis, som findes på hunde.
English: The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicinal product per kg body weight.
Danish: Den anbefalede minimumsdosis er 6,4 mg dinotefuran/kg lgv, 0,6 mg pyriproxyfen/kg lgv og 46,6 mg permethrin/kg lgv svarende til 0,12 ml af veterinærlægemidlet pr. kg lgv.
English: Vectra 3D for dogs > 40 kg
Danish: Vectra 3D for til hunde > 40 kg
English: Yellow for dogs > 4-10 kg
Danish: Gul til hunde > 4-10 kg
English: It is important to ensure that cats do not groom the site of application on a dog which has been treated with this veterinary medicinal product.
Danish: Det er vigtigt at sikre, at katten ikke slikker på applikationsstedet på den behandlede hund.
English: Fleas:
Danish: Lopper:
English: Each ml contains 54 mg dinotefuran, 4.84 mg pyriproxyfen and 397 mg permethrin.
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver ml indeholder 54 mg dinotefuran; 4,84 mg pyriproxyfen og 397 mg permethrin.
English: PHARMACEUTICAL FORM Spot-on solution.
Danish: LÆGEMIDDELFORM Spot-on-opløsning.
English: How to apply:
Danish: Sådan påføres produktet:
English: It also kills mosquitoes (Aedes aegypti) and stable flies for one month after use.
Danish: Behandlingen dræber også myg (Aedes aegypti) og stikfluer (Stomoxys calcitrans) i en måned efter applikation.
English: If in eyes, immediately flush with water.
Danish: I tilfælde af kontakt med hundens øjne, skylles øjeblikkeligt med vand.
English: • Avoid contact with the skin.
Danish: • Undgå hudkontakt med veterinærlægemidlet
English: Dogs over 40 kg body weight
Danish: Hunde over 40 kg lgv.
English: AUTHORISATION
Danish: ALTERNATIVT
English: Purple for dogs > 40 kg
Danish: Lilla til hunde > 40 kg
English: Pale yellow solution.
Danish: Bleggullig opløsning.
English: Teal
Danish: Lilla
English: Vectra 3D for dogs 1.5-4 kg for dogs > 4-10 kg
Danish: Vectra 3D til hunde 1.5-4 kg til hunde > 4-10 kg
English: Vectra 3D for dogs > 25-40 kg for dogs > 40 kg
Danish: Vectra 3D til hunde > 25-40 kg til hunde > 40 kg
English: Ticks:
Danish: Flåter:
English: Teal for dogs > 10-25 kg
Danish: Turkis til hunde > 10-25 kg
English: OR
Danish: C.
English: Dogs from 1.5 to 4 kg body weight
Danish: Hunde 1,5 - 4 kg legemsvægt (lgv.)
English: Vectra 3D for dogs > 4-10 kg for dogs > 10-25 kg
Danish: Vectra 3D til hunde > 4-10 kg til hunde > 10-25 kg
English: See package leaflet for instructions for use.
Danish: Se brugsanvisning i indlægssedlen.
English: This veterinary medicinal product does not require any special storage conditions.
Danish: Lægemidlet er ikke veterinærreceptpligtigt.
English: Special warnings for each target species:
Danish: SÆRLIG(E) ADVARSEL/ADVARSLER Særlige advarsler for hver dyreart
English: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg dinotefuran / pyriproxyfen / permethrin
Danish: Vectra 3D spot-on-opløsning til hunde 1.5-4 kg Vectra 3D spot-on-opløsning til hunde > 4-10 kg Vectra 3D spot-on-opløsning til hunde > 10-25 kg Vectra 3D spot-on-opløsning til hunde > 25-40 kg Vectra 3D spot-on-opløsning til hunde > 40 kg dinotefuran/pyriproxyfen/permethrin
English: Vectra 3D for dogs > 10-25 kg for dogs > 25-40 kg Purple
Danish: Vectra 3D til hunde > 10-25 kg til hunde > 25-40 kg
English: 4a recommendation: Gently squeeze the applicator and apply the veterinary medicinal product to the skin along the dog's back, beginning between the shoulder blades, in the number of spots and order shown in the diagrams below and squeezing until the applicator is empty.
Danish: Begynd mellem skulderbladene og tryk indtil applikatoren er tom på det antal steder og i den rækkefølge, som vises på illustrationerne nedenfor.
English: PACKAGE LEAFLET: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg
Danish: INDLÆGSSEDDEL TIL: Vectra 3D spot-on-opløsning til hunde 1,5-4 kg Vectra 3D spot-on-opløsning til hunde > 4-10 kg Vectra 3D spot-on-opløsning til hunde > 10-25 kg Vectra 3D spot-on-opløsning til hunde > 25-40 kg Vectra 3D spot-on-opløsning til hunde > 40 kg
English: Colour of applicator cap
Danish: Applikatorhættens farve
English: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg
Danish: Vectra 3D spot-on-opløsning til hunde 1.5-4 kg Vectra 3D spot-on-opløsning til hunde > 4-10 kg Vectra 3D spot-on-opløsning til hunde > 10-25 kg Vectra 3D spot-on-opløsning til hunde > 25-40 kg Vectra 3D spot-on-opløsning til hunde > 40 kg
English: Wait for the application site to dry before allowing the treated dog to come in contact with fabrics or furnishings.
Danish: Lad ikke hunden komme i kontakt med tekstiler eller møbler, før applikationsstedet er tørt.
English: ADVICE ON CORRECT ADMINISTRATION Administration:
Danish: OPLYSNINGER OM KORREKT ANVENDELSE Sådan påføres produktet:
English: 4a recommendation: Gently squeeze the applicator and apply the veterinary medicine to the skin along the dog's back, beginning between the shoulder blades, in the number of spots and order shown in the diagrams below and squeezing until the applicator is empty.
Danish: 4a-anbefalinger: Tryk forsigtigt på applikatoren og påfør veterinærlægemidlet på huden langs hundens hals.
English: Do not eat, drink or smoke while handling the veterinary medicinal product.
Danish: Særlige forholdsregler der skal træffes af personer, der administrerer lægemidlet til dyr Spis, drik eller ryg ikke, når veterinærlægemidlet håndteres.
English: If needed, the dose can be further increased up to a maximum of 1 mg once a week.
Danish: Hvis det er nødvendigt, kan dosen øges yderligere op til maksimalt 1 mg én gang om ugen.
English: The full EPAR for Ozempic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Ozempic findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Ozempic.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Ozempic.
English: After four weeks, this dose should be increased to 0.5 mg.
Danish: Efter fire uger bør dosen øges til 0,5 mg.
English: Other information about Ozempic
Danish: Andre oplysninger om Ozempic
English: Ozempic semaglutide
Danish: Ozempic semaglutid
English: It is injected under the skin of the belly, the thigh or the upper arm.
Danish: Det indsprøjtes under huden i maveskindet, låret eller overarmen.
English: Worsening of diabetic retinopathy has also been observed and will be further investigated.
Danish: Der er også observeret forværring af diabetisk retinopati, og dette vil blive undersøgt nærmere.
English: The starting dose of Ozempic is 0.25 mg once a week.
Danish: Den anbefalede dosis af Ozempic er 0,25 mg én gang ugentligt.
English: The active substance in Ozempic, semaglutide, is a ‘GLP-1 receptor agonist'.
Danish: Det aktive stof i Ozempic, semaglutid, er en "GLP-1-receptoragonist".
English: Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine).
Danish: Ozempic kan anvendes alene til patienter, som ikke kan tage metformin (et andet lægemiddel mod diabetes).
English: Side effects affecting the digestive system are considered to be manageable.
Danish: De bivirkninger ved lægemidlet, der er relateret til fordøjelsessystemet, anses for at være håndterbare.
English: What measures are being taken to ensure the safe and effective use of Ozempic?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Ozempic?
English: Serious worsening of diabetic retinopathy (damage to the retina, the light sensitive membrane at the back of the eye) is common (it may affect up to 1 in 10 people).
Danish: Alvorlig forværring af diabetisk retinopati (skade på nethinden, der er en lysfølsom membran bagerst i øjet) ses almindeligt (kan forekomme hos op til 1 ud af 10 patienter).
English: The European Medicines Agency concluded that the benefits of Ozempic seen in studies outweighed its risk and recommended it be approved for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Ozempic opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: It is not intended to provide practical advice on how to use Ozempic.
Danish: Det er ikke en praktisk vejledning i, hvordan Ozempic bør anvendes.
English: Ozempic contains the active substance semaglutide.
Danish: Ozempic indeholder det aktive stof semaglutid.
English: A further study in over 3,000 diabetes patients at high risk of heart problems showed that overall, heart attack, stroke or death occurred less frequently in patients treated with Ozempic (6.6%) than with placebo (8.9%).
Danish: En yderligere undersøgelse af over 3 000 patienter med høj risiko for hjerteproblemer viste, at hjerteanfald, slagtilfælde eller død samlet set forekom mindre hyppigt hos patienter behandlet med Ozempic (6,6 %) end hos patienter behandlet med placebo (8,9 %).
English: Five studies in over 4,000 patients showed that Ozempic lowered levels of HbA1c (a measure of blood glucose) by between 1.2 and 1.8 percentage points over 10 to 13 months.
Danish: Det er i fem undersøgelser med over 4 000 patienter påvist, at Ozempic sænkede niveauet af HbA1c (et mål for blodsukkeret) med 1,2-1,8 procentpoint i løbet af 10-13 måneder.
English: What is Ozempic and what is it used for?
Danish: Hvad er Ozempic, og hvad anvendes det til?
English: The most common side effects with Ozempic (which may affect more than 1 in 10 people) include problems with the digestive system, such as diarrhoea, vomiting and nausea (feeling sick).
Danish: De hyppigste bivirkninger ved Ozempic (som optræder hos mere end 1 ud af 10 patienter) er problemer med fordøjelsessystemet som f.eks. diarré, opkastning og kvalme.
English: When looking at the three ‘events' separately, fewer patients taking Ozempic had a heart attack or stroke, but rates of death from heart problems were similar in the two groups.
Danish: Når man ser på de tre hændelser hver for sig, oplevede færre patienter, der fik Ozempic, hjerteanfald eller slagtilfælde, men forekomsten af dødsfald som følge af hjerteproblemer var lige stor i de to grupper.
English: Why is Ozempic approved?
Danish: Hvorfor blev Ozempic godkendt?
English: These are mild or moderate in severity and of short duration.
Danish: Disse bivirkninger er kortvarige og milde til moderate af sværhedsgrad.
English: Ozempic in these studies compared favourably with other treatments, sitagliptin, exenatide and insulin glargine (which led to reductions of 0.55, 0.92, 0.83 percentage points respectively) and placebo (reductions of up to 0.09 percentage points).
Danish: I undersøgelserne havde Ozempic en bedre virkning end sitagliptin, exenatid og insulin glargin (der medførte reduktioner på hhv. 0,55, 0,92 og 0,83 procentpoint) samt placebo (der medførte en reduktion på op til 0,09 procentpoint).
English: For more information about treatment with Ozempic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Ozempic, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled.
Danish: Ozempic er et lægemiddel mod diabetes (sukkersyge), der anvendes sammen med kost og motion til behandling af voksne, hvis type 2-diabetes ikke er tilstrækkeligt reguleret.
English: What are the risks associated with Ozempic?
Danish: Hvilke risici er der forbundet med Ozempic?
English: Ozempic is available as a solution for injection in prefilled pens and can only be obtained with a prescription.
Danish: Ozempic fås som opløsning til injektion i fyldte penne og udleveres kun efter recept.
English: For the full list of all side effects and restrictions with Ozempic, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger og begrænsninger ved Ozempic fremgår af indlægssedlen.
English: Treatment with Ozempic also led to weight loss, which is considered beneficial in patients with diabetes.
Danish: Behandling med Ozempic medfører desuden et vægttab, der anses for gavnligt hos diabetespatienter.
English: Studies showed that Ozempic is effective at lowering blood glucose levels and reducing the risk of health complications in patients with type 2 diabetes.
Danish: Undersøgelser har vist, at Ozempic sænker blodsukkerniveauet og reducerer risikoen for helbredskomplikationer hos type 2-diabetikere.
English: Ozempic was also shown to be effective at reducing the occurrence of serious health complications associated with diabetes such as heart attack and stroke.
Danish: Det er også påvist, at Ozempic sænker forekomsten af en række alvorlige helbredsproblemer, der er forbundet med diabetes, f.eks. hjerteanfald og slagtilfælde.
English: For practical information about using Ozempic, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Ozempic, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: Regarding safety, this was considered in line with that of other medicines of the same class.
Danish: Sikkerhedsprofilen for Ozempic anses for at være på linje med sikkerhedsprofilen for andre lægemidler af samme klasse.
English: Ozempic was shown to be effective at controlling blood glucose levels.
Danish: Det er påvist, at Ozempic er effektivt til at regulere blodsukkeret.
English: In addition, the results indicated that treatment with Ozempic was associated with a beneficial fall in body weight.
Danish: Derudover viste resultaterne, at Ozempic medførte et gavnligt vægttab.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ozempic have been included in the summary of product characteristics and the package leaflet.
Danish: Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Ozempic.
English: What benefits of Ozempic have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Ozempic?
English: How does Ozempic work?
Danish: Hvordan virker Ozempic?
English: How is Ozempic used?
Danish: Hvordan anvendes Ozempic?
English: 720 ELISA Units
Danish: 720 ELISA enheder
English: 1 dose (1 ml) contains: Hepatitis A virus (inactivated)1,2
Danish: 1 dosis (1 ml): Hepatitis A-virus (inaktiveret)
English: 1Produced on human diploid (MRC-5) cells 2Adsorbed on aluminium hydroxide, hydrated
Danish: 1 produceret i human diploid (MRC-5)-celler 2 adsorberet på aluminiumphosphathydrat
English: 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate
Danish: 0,05 milligram Al3+ produceret i gærceller (Saccharomyces cerevisiae) ved rekombinant DNA-teknologi adsorberet på aluminiumphosphat
English: 1 pre-filled syringe +
Danish: 1 fyldt injektionssprøjte + 1 kanyle
English: (Invented) name Strength Pharmaceutical form Route of administration
Danish: Styrke Lægemiddelform Administration Primær emballage
English: Immediate Packaging
Danish: Lægemiddelform Indgivelsesvej Emballage Pakningsstørrels e
English: The tablets should be swallowed with water.
Danish: Tabletterne bør sluges med vand.
English: It is used in addition to diet and exercise as follows:
Danish: Det anvendes sammen med diæt og motion på følgende måder:
English: Glustin pioglitazone
Danish: Glustin pioglitazon
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Glustin on 11 October 2000.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Glustin den 11. oktober 2000.
English: The full EPAR for Glustin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Glustin findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Almost 7,000 patients received Glustin in all of the studies combined.
Danish: Næsten 7 000 patienter fik Glustin i alle undersøgelserne tilsammen.
English: This is a summary of the European public assessment report (EPAR) for Glustin.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Glustin.
English: Other information about Glustin:
Danish: Andre oplysninger om Glustin:
English: What measures are being taken to ensure the safe and effective use of Glustin?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Glustin?
English: The recommended starting dose of Glustin is 15 or 30 mg once a day.
Danish: Den anbefalede startdosis af Glustin er 15 eller 30 mg en gang dagligt.
English: Treatment with Glustin should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Danish: Behandlingen med Glustin skal tages op til fornyet vurdering efter tre til seks måneder og afbrydes hos patienter, der ikke får tilstrækkelig gavn af behandlingen.
English: It must also not be used in patients who have or have had bladder cancer or those with blood in the urine that has not yet been investigated.
Danish: Det må heller ikke anvendes til patienter, som har eller har haft blærekræft, eller som har blod i urinen, der endnu ikke er blevet nærmere undersøgt.
English: Glustin is a medicine that contains the active substance pioglitazone.
Danish: Glustin er et lægemiddel, der indeholder det aktive stof pioglitazon.
English: Further studies also looked at long-term use of Glustin.
Danish: Desuden blev der gennemført yderligere undersøgelser af langtidsanvendelsen af Glustin.
English: This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Danish: Denne dosis skal muligvis øges efter én til to uger til en dosis på op til 45 mg én gang om dagen, hvis der er behov for en bedre kontrol af glukosekoncentrationen (blodsukkerkoncentrationen) i blodet.
English: If Glustin is used in combination with other diabetes medicines, other side effects may occur.
Danish: Hvis Glustin anvendes i kombination med andre lægemidler mod diabetes, kan der forekomme andre bivirkninger.
English: The CHMP decided that Glustin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP besluttede, at fordelene ved Glustin opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glustin.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om, hvordan Glustin skal anvendes.
English: For more information about treatment with Glustin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Glustin, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Glustin is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Danish: Glustin anvendes til behandling af type 2 diabetes hos voksne (i alderen 18 år og derover), især de overvægtige.